Foundation Medicine to develop companion diagnostics for Lilly’s Retevmo and Loxo Oncology at Lilly’s pipeline

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Foundation Medicine Inc. and Eli Lilly and Company entered a collaboration for the development of Foundation Medicine’s tissue- and blood-based assays as companion diagnostics for Retevmo (selpercatinib) and other therapies in Loxo Oncology at Lilly’s pipeline. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents


Veeva Systems formed a ten-year strategic partnership agreement with Merck, that builds on the existing 12-year partnership between the companies. Under the terms of the agreement, Merck will take a Veeva-first approach to new industry-specific software and data, selecting Veeva products when they are fit for purpose to maximize the value of Veeva’s integrated, cloud-based platform and products.